Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Weighing the outcomes.

Michael J Russo1, David Balekdjian

  • 1The Bruckner Group, 27 Water Street, Suite 409, Wakefield, MA 01880, USA.

Nature Biotechnology
|February 9, 2008
PubMed
Summary
This summary is machine-generated.

The healthcare industry is shifting towards a value-based model. Pharmaceutical companies must adapt their strategies to succeed in this evolving landscape.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.

Bioorganic & medicinal chemistry letters·2012
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
Same journal

Experiment-guided AlphaFold3 resolves measurement-consistent protein ensembles.

Nature biotechnology·2026
See all related articles

Area of Science:

  • Healthcare Economics
  • Pharmaceutical Industry Analysis
  • Health Policy

Background:

  • The traditional fee-for-service healthcare model is being replaced by a focus on patient outcomes and cost-effectiveness.
  • This transition, termed the 'healthcare value era,' presents significant challenges and opportunities for all stakeholders.
  • Pharmaceutical companies face increasing pressure to demonstrate the value of their products beyond clinical efficacy.

Purpose of the Study:

  • To analyze the implications of the healthcare value era for pharmaceutical firms.
  • To identify the strategic imperatives for drug companies to thrive in this new environment.
  • To provide actionable insights for navigating the evolving healthcare landscape.

Main Methods:

  • Review of current healthcare economic trends and policy shifts.

Related Experiment Videos

  • Analysis of industry reports and market research on pharmaceutical value demonstration.
  • Case study examination of companies adapting to value-based healthcare.

    • Main Results:

    • The healthcare value era necessitates a shift from volume-based sales to outcome-based value propositions.
    • Key consequences include increased demand for real-world evidence, innovative pricing models, and patient-centric approaches.
    • Early adopters are demonstrating success through strategic alignment with payer and provider priorities.

    Conclusions:

    • Pharmaceutical firms must proactively redefine their business models to align with value-based healthcare principles.
    • Strategic adaptation is crucial for long-term sustainability and competitiveness in the emergent healthcare value era.
    • Embracing innovation in R&D, market access, and commercialization is essential for demonstrating and capturing value.